Table 1.
Clinical End Points of Any Cardiovascular Event, Cardiovascular Death, and Composite Cardiovascular End Point by Clinical Event in Placebo (n=1935) and Cinacalcet Groups (n=1948)
| Event Type | Any Cardiovascular Event | Cardiovascular Death | ||
|---|---|---|---|---|
| Placebo | Cinacalcet | Placebo | Cinacalcet | |
| Myocardial infarction | 111 (14.4) | 129 (17.3) | 29 (7.4) | 27 (7.2) |
| Stroke | 79 (10.2) | 94 (12.6) | 34 (8.7) | 48 (12.7) |
| Heart failure | 203 (26.3) | 165 (22.1) | 34 (8.7) | 20 (5.3) |
| Hospitalization for unstable angina | 47 (6.1) | 31 (4.2) | — | — |
| Peripheral vascular event | 152 (19.7) | 150 (20.1) | — | — |
| Fatal pulmonary embolism | 2 (0.3) | 5 (0.7) | 4 (1.0) | 6 (1.6) |
| Sudden death | 115 (14.9) | 109 (14.6) | 182 (46.5) | 166 (44.0) |
| Death from cardiovascular procedure | 4 (0.5) | 6 (0.8) | 7 (1.8) | 15 (4.0) |
| Other fatal cardiovascular event | 15 (1.9) | 21 (2.8) | 33 (8.4) | 36 (9.5) |
| Unknown cardiovascular death cause | 44 (5.7) | 36 (4.8) | 68 (17.4) | 59 (15.6) |
| Total, n | 772 | 746 | 391 | 377 |
Values are n (%). There were no statistically significant differences in the distribution of the component clinical events between the group randomized to placebo and the group randomized to cinacalcet; χ2 P=0.159 and 0.155 for any cardiovascular event end point and cardiovascular death, respectively.